Adcendo
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.
$75MSeries C
Role not disclosedT
TPG
Activity from announced rounds
Activity in this selectionBiotech
TPG is the investment firm identified by Adcendo, Crusoe and in its own Cambridge Mobile Telematics announcement.
Recorded funding activity
Adcendo develops targeted cancer medicines. Crusoe develops computing infrastructure, while CMT supplies road-safety intelligence. The firm-level attribution does not select an unnamed Life Sciences, Rise, Growth or other vehicle.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $75M 1 disclosed · full round size, not this investor’s share